Erika P. Hamilton, MD, discusses the key safety and efficacy findings from the phase 3 DESTINY-Breast03 study.
Erika P. Hamilton, MD, lead investigator and director of the Breast and Gynecologic Cancer Research Program at the Sarah Cannon Research Institute/Tennessee Oncology, discusses the key safety and efficacy findings from the phase 3 DESTINY-Breast03 study (NCT03529110).
According to the safety update of the study, 54.9% of patients discontinued from receiving treatment trastuzumab deruxtecan-nxki (Enhertu) vs 85.1% who discontinued T-DM1. Between arms, the rates of treatment-emergent adverse events (TEAEs) were similar and any-grade TEAEs were experienced by 99.6% of the trastuzumab deruxtecan arm vs 95.4% in the T-DM1 arm.
TEAEs which were grade 3 or greater were experienced by 53.3% and 49.8% for each arm, and serious TEAEs of any grade were seen in 21.0% of patients in the trastuzumab deruxtecan arm and 19.2% of patients in the T-DM1 arm, respectively. Additionally, grade 3 or greater serious TEAEs were observed in 15.2% and 14.6% of patients for each treatment, respectively.
Transcription:
0:08 | The main efficacy finding with DESTINY-Breast03 was reported previously and showed a 72% reduction in the risk of progression, so really outstanding results compared with T-DM1 which previously was our standard in the second-line setting. Again, what we saw was although things like nausea, vomiting, and hair loss were more common with trastuzumab deruxtecan, overall serious events, or grade 3 or greater events, were very similar between the arms.
0:41 | When we use these exposure adjusted incidence rates to compare how many AEs were happening compared with how long patients could remain on the therapy and continue to get benefit, we saw that, almost across the board, those were lower with trastuzumab deruxtecan than T-DM1.
UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC
April 8th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.
Read More
Survival and Safety Outcomes Factor into Use of Sacituzumab Govitecan in HR+ Breast Cancer
March 29th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Experts Warn of Radiation Overtreatment in Older Women With Early-Stage Breast Cancer
March 20th 2024Studies have found that omitting radiation therapy after breast-conserving surgery and/or omitting axillary surgery in women age 70 years or older does not affect their survival when taking endocrine therapy.
Read More
Analyzing ADC Treatment Sequencing in Advanced Breast Cancer
March 15th 2024In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Read More